View a Summary of the 2016 CIBRN Learning Program: Video Learning MicroModule Now Available Online

As we get ready to kick off our second year of the CIBRN learning program, we invite you to review the CIBRN micromodule video from the 2016 season. The video is under 20 minutes in length and will provide an overview of discussions surrounding structured questions authored by CIBRN Leaders.

Watch the 2016 CIBRN micromodules here:

English: http://studio7web.ca/clients/Legitimed/CIBRN_BiosimilarSummary/English/

Français: http://studio7web.ca/clients/Legitimed/CIBRN_BiosimilarSummary/French/

Recording of CIBRN Dermatology Webinar Now Available Online

We invite you to listen to an in-depth discussion of CIBRN Question #5 & Question #6, as presented by Dr. Gordon Searles, Dr. Ronald Vender and Dr. Mark Kirchhof, recorded at the CIBRN Dermatology Webinar, December 8, 2016. Link to recorded webinar.

CIBRN Question #5: Given that biosimilar trials are to be compared against the originator using a “most sensitive” indication or condition, how will the trial indication be selected for study? Link to discussion on Sosido.

CIBRN Question #6: Can the concept of extrapolation be used for biosimilars in patients with hidradenitis suppurativa given their major treatment differences? Link to discussion on Sosido.

Webinar for CIBRN Dermatology Subgroup, presented by Dr. Gordon Searles, Dr. Ronald Vender & Dr. Mark Kirchhof, Thurs, Dec 8, 7:00 pm EST

Please join Dr. Gordon Searles, Dr. Ronald Vender and Dr. Mark Kirchhof for an in-depth discussion of CIBRN Question #5 and Question #6 surrounding the implications of the evolving Biosimilar landscape on clinical practice and patient health in Canada.

This webinar is intended for the CIBRN Dermatology subgroup and is scheduled for Thursday, December 8th, 7:00-8:00pm EST. See instructions below:

Step 1: To join the audio portion:
Dial toll-free:  1-866-830-9434
Enter Participant Code: 7994216

Step 2: To join the web portion:
Click on link: https://studio7communications.adobeconnect.com/cibrn_dermatology/
Select ‘Next’
Select ‘Guest’
Enter your name
Select ‘Enter’

Prior to the webinar, you are invited to visit the CIBRN community on Sosido to review the questions & responses and to reply with your personal clinical perspectives. The webinar will be recorded and archived for future viewing by the CIBRN community.

If you have any comments or questions, please contact me at your convenience.

Paul Abbass
LEGITIMED INC.
Email: paul.abbass@legitimed.com

—————-
If you have never attended an Adobe Connect meeting before:

Test your connection: https://studio7communications.adobeconnect.com/common/help/en/support/meeting_test.htm

Get a quick overview: http://www.adobe.com/products/adobeconnect.html

Recording of CIBRN Rheumatology Webinar Now Available Online

We invite you to listen to an in-depth discussion of CIBRN Question #3 & Question #4, as presented by Dr. Carter Thorne and Dr. Philip Baer, recorded at the CIBRN Rheumatology Webinar, December 1, 2016. Link to recorded webinar.

CIBRN Question #3: How confident can rheumatologists be in the results of the Nor-switch study to inform their biologic choices in everyday practice? Link to discussion on Sosido.

CIBRN Question #4: Given that patients in Nor-switch had been on an originator infliximab for a mean of 6+ years, is the rate of disease worsening over 1 year of 26-29% concerning regarding the face validity of the study? Link to discussion on Sosido.

Webinar for CIBRN Rheumatology Subgroup with Dr. Carter Thorne and Dr. Philip Baer, Thurs, Dec 1, 6:30 pm EST

Please join Dr. Carter Thorne and Dr. Philip Baer for an in-depth discussion pertaining to CIBRN Question 3 & Question 4 surrounding the implications of the evolving Biosimilar landscape on clinical practice and patient health in Canada.

This webinar is intended for the CIBRN Rheumatology subgroup and is scheduled for Thursday, December 1st 6:30-7:30pm EST. See instructions below:

Step 1: To join the audio portion:
Dial toll-free: 1-866-830-9434
Enter Participant Code: 7994216

Step 2: To join the web portion:
Click on link: https://studio7communications.adobeconnect.com/cibrn_rheumatology/
Select ‘Next’
Select ‘Guest’
Enter your name
Select ‘Enter’

Prior to the webinar, you are invited to visit the CIBRN community on Sosido to review the questions & responses and to reply with your personal clinical perspectives. The webinar will be recorded and archived for future viewing by the CIBRN community.

If you have any comments or questions, please contact me at your convenience.

Paul Abbass
LEGITIMED INC.
Email: paul.abbass@legitimed.com


If you have never attended an Adobe Connect meeting before:

Test your connection: https://studio7communications.adobeconnect.com/common/help/en/support/meeting_test.htm

Get a quick overview: http://www.adobe.com/products/adobeconnect.html

Recording of CIBRN Gastroenterology Webinar Now Available Online

We invite you to listen to an in-depth discussion of Question #1 and Question #2 in the CIBRN community on Sosido, as presented by Dr. Vipul Jairath and Dr. David Morgan, recorded at the CIBRN Gastroenterology Webinar, November 24, 2016. Link to recorded webinar.

Question #1: Based on data presented so far, is there sufficient evidence to consider non-medical switching of biologics in stable patients on treatment? If no, what data would you wish to see before you do this in your clinical practice. Link to discussion on Sosido.

Question #2: Based on data published to this point, when starting a patient on infliximab do you think we should be using originator molecules, only biosimilars or either molecule in naïve patients? What factors influence your considerations? Link to discussion on Sosido.

Webinar for CIBRN Gastroenterology Subgroup with Dr. Vipul Jairath and Dr. David Morgan, Thurs, Nov 24, 7:30 pm EST

Please join Dr. Vipul Jairath and Dr. David Morgan for an hour-long webinar to discuss and deep dive on CIBRN Question 1 & Question 2 surrounding the implications of the evolving Biosimilar landscape on clinical practice and patient health.

This webinar is intended for the CIBRN Gastroenterology subgroup and is scheduled for Thursday, November 24th 7:30-8:30pm EST. See instructions below:

Step 1: To join the audio portion:
Dial toll-free: 1-866-830-9434
Enter Participant Code: 7994216

Step 2: To join the web portion:
Click on link: https://studio7communications.adobeconnect.com/cibrn_gastroenterology
Select ‘Next’
Select ‘Guest’
Enter your name
Select ‘Enter’

Prior to the webinar, you are invited to visit the CIBRN community on Sosido to review the questions & responses and to reply with your personal clinical perspectives. The webinar will be recorded and archived for future viewing by the CIBRN community.

If you have any comments or questions, please contact paul.abbass@legitimed.com

—————-
If you have never attended an Adobe Connect meeting before:

Test your connection: https://studio7communications.adobeconnect.com/common/help/en/support/meeting_test.htm

Get a quick overview: http://www.adobe.com/products/adobeconnect.html